IFNB1 and neoplasm: Immunotherapy can include checkpoint inhibitors, adoptive cell therapies, and cancer vaccines, among other approaches.46 47 There are many cancer vaccine delivery methods, including through intratumoral and localized mucosal routes.48–51 However, these delivery methods are invasive, therefore limiting the number of participants willing to take part in clinical settings.52–54 An alternative approach is to target tdLNs, which are known to accumulate tumor antigens that can be used to prime antitumor T cell responses.55 In our study, we show that Alb-IFNβ is able to target the tdLNs (figure 2).